This study was funded by Sandoz Biopharmaceuticals.
Biosimilar granulocyte–colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?
Article first published online: 26 JUN 2014
© 2014 The Authors. Transfusion published by Wiley Periodicals, Inc. on behalf of AABB.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 55, Issue 2, pages 430–439, February 2015
How to Cite
Bonig, H., Becker, P. S., Schwebig, A. and Turner, M. (2015), Biosimilar granulocyte–colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?. Transfusion, 55: 430–439. doi: 10.1111/trf.12770
- Issue published online: 12 FEB 2015
- Article first published online: 26 JUN 2014
- Manuscript Accepted: 27 MAY 2014
- Manuscript Revised: 22 MAY 2014
- Manuscript Received: 27 FEB 2014
- Sandoz International GmbH
- 1European Medicines Agency. Scientific guidelines on biosimilar medicines. EMA, London, 2005-2013 [cited 2013 Nov 6]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c
- 2Food and Drug Administration (FDA). Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), February 2012 [cited 2014 Mar 5]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128
- 3Australian Therapeutic Goods Administration (TGA). Evaluation of biosimilars. Version 1.0, July 2013 [cited 2014 May 19]. Available from: http://www.tga.gov.au/pdf/pm-argpm-biosimilars.pdf
- 5Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl2012;2:279-335.
- 11Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature. Haematologica2006;91:e26-28., , , et al.
- 15Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol2006;135:642-650., , , et al.
- 20Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study. Vox Sang2013;104:46-54., , , et al.
- 21European Group for Blood and Marrow Transplantation (EBMT). Position statement: biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donors. 2009 [cited 2014 Feb 27]. Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/Biosimilars/Biosimilars_9Jan09.pdf
- 23Austrian Society of Hematology and Oncology position on biosimilars. Mag Eur Med Oncol2009;4:232-233., , , et al.
- 24Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica2011;96:937-942., , , et al.
- 25Japan Society for Hematopoietic Cell Transplantation. Position statement of the Japan Society for Hematopoietic Cell Transplantation regarding the use of biosimilar granulocyte-colony stimulating factors for the mobilization of hematopoietic stem cells in healthy donors. April 2013 [cited 2014 Feb 18]. Available from: http://www.jshct.com/english
- 31XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol2009;4:736-740., , , et al.
- 36Comparison of two formulations of filgrastim, Neupogen (Amgen) and Zarzio (Sandoz), used to accelerate neutrophil recovery after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant2012;47(Suppl 1):S316 (P872)., , , et al.
- 38Biosimilar G-CSF is effective in reducing the duration of neutropenia after autologous bone marrow transplantation. Bone Marrow Transplant2012;47(Suppl 1):S316 (P873)., , , et al.
- 39Experiences of autologous peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with “biosimilar” filgrastim (Zarzio®, Sandoz, granulocyte colony-stimulating factor). Bone Marrow Transplant2013;48(Suppl 2):S114 (P519)., , , et al.
- 40Biosimilar compared with originator filgrastim for related-donor allogeneic stem cell mobilisation: a prospective-historical control study. Presented at the 55th Annual Meeting of the American Society of Haematology (ASH), New Orleans, LA, USA, December 7-10, 2013., , , et al.
- 41Zarzio plus chemotherapy as peripheral blood stem cell mobilization strategy in patients with haematological diseases candidated to autologous stem cell transplantation. Bone Marrow Transplant2013;48(Suppl 2):S120 (P529)., , , et al.
- 43Use of biosimilar G-CSF compared with lenograstim in autologous haematopoietic stem cell transplant and in sibling allogeneic transplant. Presented at the 55th Annual Meeting of the American Society of Haematology (ASH), New Orleans, LA, USA, December 7-10, 2013., , .
- 45Safety and efficacy of a G-CSF biosimilar (Zarzio®) for haematopoietic progenitor cell mobilization in patients with haematological malignancies. Bone Marrow Transplant2013;48(Suppl 2):S112 (P515)., , , et al.
- 46Use of a biosimilar G-CSF in allogeneic stem cell mobilisation. Bone Marrow Transplant2012;47(Suppl 1):S316 (P727)., , , et al.
- 47Safety and efficacy of a G-CSF biosimilar (Zarzio®) for haematopoietic progenitor cell mobilization in allogeneic healthy donors. Bone Marrow Transplant2013;48(Suppl 2):S102 (P491)., , , et al.
- 49Biosimilar filgrastim mobilizes haematopoietic stem cells in healthy volunteer donors with expected efficiency and typical acute adverse effects: interim results of a post-authorization safety study. Bone Marrow Transplant2013;48(Suppl 2):S28 (O177)., , , et al.
- 52World Marrow Donor Association (WMDA). Donor medical suitability recommendations. 2013 [cited 2014 May 19]. Available from: http://www.worldmarrow.org/donorsuitability/index.php/Main_Page
- 53Foundation for the Accreditation of Cellular Therapy/Joint Accreditation Committee—ISCT & EBMT (FACT/JACIE). Cellular therapy standards. 2013 [cited 2014 May 19]. Available from: http://www.factwebsite.org/ctstandards/
- 58Granulocyte colony-stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview on safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant2007;40:185-192., , , et al.
- 69Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant1996;17(Suppl 2):S19-21., , , et al.